Chemical Biology & Drug Design · 2010 · 44 citations · 45 references
MedicineMedicinal ChemistryPharmacologyApoptosisCancer PharmacologyMolecular PharmacologyAntineoplastic Drug ClassesApoptosis PharmacologyOncology PharmacologyAnti-apoptotic AgentsAnticancer ActivityAntiproliferative Drug ActionCellular ProliferationPro-apoptotic AgentsPro-apoptotic ProteinsStructure-based ScreeningViable Cell Count
Naturally occurring xanthones have been documented as having antitumor properties, with some of them presently undergoing clinical trials. In an attempt to improve the biological activities of dihydroxyxanthones, prenylation and other molecular modifications were performed. All the compounds reduced viable cell number in a leukemia cell line K-562, with the fused xanthone 3,4-dihydro-12-hydroxy-2,2-dimethyl-2H,6H-pyrano[3,2-b]xanthen-6-one (5) being the most potent. The pyranoxanthone 5 was particularly effective in additional leukemia cell lines (HL-60 and BV-173). Furthermore, the pyranoxanthone 5 decreased cellular proliferation and induced an S-phase cell cycle arrest. In vitro, the pyranoxanthone 5 increased the percentage of apoptotic cells which was confirmed by an appropriate response at the protein level (e.g., PARP cleavage). Using a computer screening strategy based on the structure of several anti- and pro-apoptotic proteins, it was verified that the pyranoxanthone 5 may block the binding of anti-apoptotic Bcl-xL to pro-apoptotic Bad and Bim. The structure-based screening revealed the pyranoxanthone 5 as a new scaffold that may guide the design of small molecules with better affinity profile for Bcl-xL.
45
Molecular cloning: A laboratory manual
Prescott L. Deininger · Analytical Biochemistry · 1990 · 86.2K citations
Helen M. Berman · Nucleic Acids Research · 2000 · 39.8K citations
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Jiangen Gong, Antonio Costanzo, Hongqiong Yang et al. · Nature · 1999 · 928 citations